Alnylam Pharmaceuticals Inc Earnings
The next earnings date for Alnylam Pharmaceuticals Inc is July 30, 2026.
They are scheduled to announce earnings before the market opens that day.
Analyst Estimates of Alnylam Pharmaceuticals Inc Earnings
| 07/30/2026 | $1.46 |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
Alnylam Pharmaceuticals Inc Earnings: Historical
| 04/30/2026 | Before Market | $1.99 | 35.37% |
| 02/12/2026 | Before Market | $1.25 | -16.67% |
| 10/30/2025 | Before Market | $2.90 | 65.71% |
| 07/31/2025 | Before Market | $0.32 | 113.33% |
| 05/01/2025 | Before Market | $-0.01 | 97.30% |
| 02/13/2025 | Before Market | $0.06 | 142.86% |
| 10/31/2024 | Before Market | $-0.50 | -28.21% |
| 08/01/2024 | Before Market | $0.56 | 181.16% |
| 05/02/2024 | Before Market | $-0.16 | 74.60% |
| 02/15/2024 | Before Market | $-0.77 | 0.00% |
More About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
“Alnylam Pharmaceuticals Inc Earnings” Can Refer to the Alnylam Pharmaceuticals Inc Earnings Date
Some people say “Alnylam Pharmaceuticals Inc earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my Alnylam Pharmaceuticals Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning Alnylam Pharmaceuticals Inc Stock on the Earnings Date
If you own Alnylam Pharmaceuticals Inc stock (ALNY) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Alnylam Pharmaceuticals Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading Alnylam Pharmaceuticals Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Learning More Alnylam Pharmaceuticals Inc Earnings
You can contact us any time if you would like to ask questions about Alnylam Pharmaceuticals Inc earnings or anything else related to the stock market.